BR0315980A - Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos - Google Patents

Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos

Info

Publication number
BR0315980A
BR0315980A BR0315980-9A BR0315980A BR0315980A BR 0315980 A BR0315980 A BR 0315980A BR 0315980 A BR0315980 A BR 0315980A BR 0315980 A BR0315980 A BR 0315980A
Authority
BR
Brazil
Prior art keywords
canine
antigens
immunological diagnosis
human ehrlichiosis
gene
Prior art date
Application number
BR0315980-9A
Other languages
English (en)
Other versions
BRPI0315980B1 (pt
Inventor
Jere W Mcbride
David H Walker
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of BR0315980A publication Critical patent/BR0315980A/pt
Publication of BRPI0315980B1 publication Critical patent/BRPI0315980B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTìGENOS P153 E P156 PARA O DIAGNóSTICO IMUNOLóGICO DA EHRLICHIOSE CANINA E HUMANA E USOS DOS MESMOS". A presente invenção refere-se a seq³ências que codificam duas glicoproteínas imunorreativas foram cionadas de Ehrlichia canis (gene p153) e de Ehrlichia chaffeensis (gene p156). Estas duas glicoproteínas são ortólogos imunorreativos específicos à espécie que são úteis como vacinas em subunidades e para diagnósticos sorológicos e moleculares para E. canis e E. chaffeensis.
BRPI0315980A 2002-11-04 2003-11-04 dna codificando o antígeno p156 de ehrlichia chaffeensis, vetor, célula hospedeira, vacina compreendendo o mesmo, processos para determinar se um cão está infectado com ehrlichia chaffeensis e kits para a realização dos referidos processos BRPI0315980B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357302P 2002-11-04 2002-11-04
PCT/US2003/034916 WO2004042037A1 (en) 2002-11-04 2003-11-04 P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof

Publications (2)

Publication Number Publication Date
BR0315980A true BR0315980A (pt) 2005-09-20
BRPI0315980B1 BRPI0315980B1 (pt) 2016-03-29

Family

ID=32312680

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315980A BRPI0315980B1 (pt) 2002-11-04 2003-11-04 dna codificando o antígeno p156 de ehrlichia chaffeensis, vetor, célula hospedeira, vacina compreendendo o mesmo, processos para determinar se um cão está infectado com ehrlichia chaffeensis e kits para a realização dos referidos processos

Country Status (13)

Country Link
US (2) US7204992B2 (pt)
EP (1) EP1581638B1 (pt)
JP (1) JP4494974B2 (pt)
KR (1) KR101063177B1 (pt)
CN (2) CN101294162B (pt)
AT (1) ATE372378T1 (pt)
AU (1) AU2003290575B2 (pt)
BR (1) BRPI0315980B1 (pt)
CA (1) CA2504762A1 (pt)
DE (1) DE60316189T2 (pt)
ES (1) ES2293057T3 (pt)
MX (1) MXPA05004804A (pt)
WO (1) WO2004042037A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928463T3 (es) 2005-04-04 2022-11-18 Idexx Lab Inc DIVA (que diferencia animales infectados de vacunados) de Ehrlichia canis
US7842474B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
CA2612302C (en) 2005-06-16 2015-07-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
ES2618842T3 (es) 2007-09-11 2017-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vacuna atenuada para la erliquiosis
CA2700476C (en) 2007-09-21 2017-11-28 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis variable-length pcr target
EP2045816A1 (en) * 2007-10-01 2009-04-08 Paul Scherrer Institut Fast readout method and swiched capacitor array circuitry for waveform digitizing
KR101621038B1 (ko) 2007-10-31 2016-05-16 아이덱스 래보러토리즈, 인코포레이티드 에를리히아 카니스 ｄｉｖａ（감염된 동물을 백신접종된 동물과 구별）
JP5677703B2 (ja) 2008-01-10 2015-02-25 リサーチ ディベロップメント ファウンデーション Ｅｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓにのためのワクチンおよび診断
WO2011063235A2 (en) * 2009-11-20 2011-05-26 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
RU2603274C2 (ru) * 2010-07-02 2016-11-27 Интервет Интернэшнл Б.В. Вакцина против ehrlichia canis
JP6325553B2 (ja) 2012-10-11 2018-05-16 アバクシス， インコーポレイテッド エールリヒア抗体の検出のためのペプチド、デバイス、および方法
US9194870B2 (en) 2014-01-21 2015-11-24 Abaxis, Inc. Peptides, devices, and methods for the detection of Anaplasma antibodies
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
MX2022000525A (es) * 2019-07-12 2022-04-20 Res Found Dev Vacunas contra la ehrlichia y composiciones inmunogenicas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653128B2 (en) * 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US6403093B1 (en) * 1997-03-21 2002-06-11 Mayo Foundation For Medical Education And Research Methods to detect granulocytic ehrlichiosis
US6207169B1 (en) * 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
AU3483599A (en) * 1998-04-09 1999-11-01 Ohio State Research Foundation, The Nucleic acids encoding outer membrane protein of human granulocytic ehrlichiosisagent
US6436399B1 (en) * 1998-04-09 2002-08-20 The Ohio State University Research Foundation Nucleic acid encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6544517B1 (en) * 1998-09-18 2003-04-08 The Ohio State University Research Foundation Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis
US6355777B1 (en) * 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
US6512005B2 (en) 2001-02-28 2003-01-28 Taro Pharmaceutical Industries, Ltd. Process for synthesis of pure warfarin acid, warfarin alkali metal salts and corresponding clathrates

Also Published As

Publication number Publication date
EP1581638A1 (en) 2005-10-05
EP1581638A4 (en) 2005-12-28
WO2004042037A1 (en) 2004-05-21
CN100386430C (zh) 2008-05-07
JP2006505270A (ja) 2006-02-16
AU2003290575A1 (en) 2004-06-07
CN1735684A (zh) 2006-02-15
ATE372378T1 (de) 2007-09-15
US20040121433A1 (en) 2004-06-24
EP1581638B1 (en) 2007-09-05
DE60316189T2 (de) 2007-12-20
KR101063177B1 (ko) 2011-09-08
JP4494974B2 (ja) 2010-06-30
KR20050084679A (ko) 2005-08-26
CA2504762A1 (en) 2004-05-21
BRPI0315980B1 (pt) 2016-03-29
US7204992B2 (en) 2007-04-17
ES2293057T3 (es) 2008-03-16
CN101294162A (zh) 2008-10-29
MXPA05004804A (es) 2005-12-05
US20070218082A1 (en) 2007-09-20
US7754224B2 (en) 2010-07-13
DE60316189D1 (de) 2007-10-18
CN101294162B (zh) 2011-03-30
AU2003290575B2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
BR0315980A (pt) Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
BRPI0408635A (pt) emulsões de óleo em água microfluidizadas e composições de vacinas
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DE69331901T2 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
RS52188B (en) A PSYCHI VACCINE FOR THE PROTECTION OF ERLIHIOSIS
ES2148799T3 (es) Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio.
HK1072264A1 (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2346314T3 (es) Antigenos de b. pertussis y uso de los mismos en vacunacion.
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
EA200900338A1 (ru) Вакцины против хламидийной инфекции
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
ES2114687T3 (es) Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.
DK0954529T3 (da) Porphyromonas gingivalis-antigener til diagnose og behandling af rodbetændelse
DE60019178D1 (de) Neue Antigenklasse von Geflügelreoviren
BR9611455A (pt) Compostos e métodos para a detecção e prevenção de infecção por t. cruzi.
AR078539A1 (es) Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas
Hartmann et al. A nematode allergen elicits protection against challenge infection under specific conditions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/03/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.